Cargando…

Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program

Melanoma plasticity creates a plethora of opportunities for cancer cells to escape treatment. Thus, therapies must target all cancer cell subpopulations bearing the potential to contribute to disease. The role of the differentiation/pigmentation program in intrinsic and acquired drug resistance is l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Czyz, Malgorzata, Sztiller-Sikorska, Malgorzata, Gajos-Michniewicz, Anna, Osrodek, Marta, Hartman, Mariusz L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636509/ https://www.ncbi.nlm.nih.gov/pubmed/31354817 http://dx.doi.org/10.1155/2019/1697913

Ejemplares similares

Exogenous growth factors bFGF, EGF and HGF do not influence viability and phenotype of (V600E)BRAF melanoma cells and their response to vemurafenib and trametinib in vitro
por: Zalesna, Izabela, et al.
Publicado: (2017)

Insulin Reduces the Efficacy of Vemurafenib and Trametinib in Melanoma Cells
por: Osrodek, Marta, et al.
Publicado: (2020)

Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity
por: Hartman, Mariusz L., et al.
Publicado: (2020)

17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAF(V600E) inhibitors in melanoma cells of different genetic subtypes
por: Mielczarek-Lewandowska, Aleksandra, et al.
Publicado: (2019)

TYRP1 mRNA level is stable and MITF-M-independent in drug-naïve, vemurafenib- and trametinib-resistant BRAF(V600E) melanoma cells
por: Hartman, Mariusz L., et al.
Publicado: (2019)

Natural Compounds' Activity against Cancer Stem-Like or Fast-Cycling Melanoma Cells
por: Sztiller-Sikorska, Malgorzata, et al.
Publicado: (2014)

Physiologically Relevant Oxygen Concentration (6% O(2)) as an Important Component of the Microenvironment Impacting Melanoma Phenotype and Melanoma Response to Targeted Therapeutics In Vitro
por: Osrodek, Marta, et al.
Publicado: (2019)

MCL-1, BCL-X(L) and MITF Are Diversely Employed in Adaptive Response of Melanoma Cells to Changes in Microenvironment
por: Hartman, Mariusz L., et al.
Publicado: (2015)

WNT Signaling in Melanoma
por: Gajos-Michniewicz, Anna, et al.
Publicado: (2020)

Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-M(high) melanoma cell populations
por: Hartman, Mariusz L., et al.
Publicado: (2016)

Role of miRNAs in Melanoma Metastasis
por: Gajos-Michniewicz, Anna, et al.
Publicado: (2019)

Pro-Apoptotic Activity of MCL-1 Inhibitor in Trametinib-Resistant Melanoma Cells Depends on Their Phenotypes and Is Modulated by Reversible Alterations Induced by Trametinib Withdrawal
por: Hartman, Mariusz L., et al.
Publicado: (2023)

Parthenolide reduces the frequency of ABCB5-positive cells and clonogenic capacity of melanoma cells from anchorage independent melanospheres
por: Czyz, Malgorzata, et al.
Publicado: (2013)

Gene Expression Profiling Identifies Microphthalmia-Associated Transcription Factor (MITF) and Dickkopf-1 (DKK1) as Regulators of Microenvironment-Driven Alterations in Melanoma Phenotype
por: Hartman, Mariusz L., et al.
Publicado: (2014)

Parthenolide as Cooperating Agent for Anti-Cancer Treatment of Various Malignancies
por: Sztiller-Sikorska, Malgorzata, et al.
Publicado: (2020)

WNT/β-catenin signaling in hepatocellular carcinoma: The aberrant activation, pathogenic roles, and therapeutic opportunities
por: Gajos-Michniewicz, Anna, et al.
Publicado: (2023)

Melanoma-Derived Extracellular Vesicles Bear the Potential for the Induction of Antigen-Specific Tolerance
por: Düchler, Markus, et al.
Publicado: (2019)

Pentoxifylline Inhibits WNT Signalling in β-Catenin(high) Patient-Derived Melanoma Cell Populations
por: Talar, Beata, et al.
Publicado: (2016)

Trametinib-Resistant Melanoma Cells Displaying MITF(high)/NGFR(low)/IL-8(low) Phenotype Are Highly Responsive to Alternating Periods of Drug Withdrawal and Drug Rechallenge
por: Koziej, Paulina, et al.
Publicado: (2023)

Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma
por: Mistry, Hitesh B., et al.
Publicado: (2017)

MITF in melanoma: mechanisms behind its expression and activity
por: Hartman, Mariusz L., et al.
Publicado: (2014)

Inhibitors of HSP90 in melanoma
por: Mielczarek-Lewandowska, Aleksandra, et al.
Publicado: (2019)

Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer
por: Joshi, Monika, et al.
Publicado: (2015)

Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients
por: Daud, Adil, et al.
Publicado: (2017)

Histone Deacetylases (HDAC) Inhibitor—Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor
por: Drzewiecka, Małgorzata, et al.
Publicado: (2023)

Structural and Biofunctional Insights into the Cyclo(Pro-Pro-Phe-Phe-) Scaffold from Experimental and In Silico Studies: Melanoma and Beyond †
por: Bojarska, Joanna, et al.
Publicado: (2022)

PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas
por: Czyż, Małgorzata, et al.
Publicado: (2016)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China
por: Gao, Tianfu, et al.
Publicado: (2021)

Metastatic melanoma and vemurafenib: novel approaches
por: De Mello, Ramon Andrade
Publicado: (2012)

A STATement on Vemurafenib-Resistant Melanoma
por: Hartsough, Edward J., et al.
Publicado: (2013)

BCL-w: apoptotic and non-apoptotic role in health and disease
por: Hartman, Mariusz L., et al.
Publicado: (2020)

BCL-G: 20 years of research on a non-typical protein from the BCL-2 family
por: Hartman, Mariusz L., et al.
Publicado: (2023)

17-Aminogeldanamycin Inhibits Constitutive Nuclear Factor-Kappa B (NF-κB) Activity in Patient-Derived Melanoma Cell Lines
por: Hartman, Mariusz L., et al.
Publicado: (2020)

Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model
por: Kawaguchi, Kei, et al.
Publicado: (2016)

Trametinib: A Targeted Therapy in Metastatic Melanoma
por: Hoffner, Brianna, et al.
Publicado: (2018)

Bioenergetic modulation with the mitochondria uncouplers SR4 and niclosamide prevents proliferation and growth of treatment-naïve and vemurafenib-resistant melanomas
por: Figarola, James L., et al.
Publicado: (2018)

Targeting Genome Stability in Melanoma—A New Approach to an Old Field
por: Osrodek, Marta, et al.
Publicado: (2021)

Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours
por: Tate, Sonya C, et al.
Publicado: (2016)

Resistance to Vemurafenib Can Be Reversible After Treatment Interruption: A Case Report of a Metastatic Melanoma Patient
por: Mackiewicz-Wysocka, Małgorzata, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_63udm2uet5aigf90sdoifligts